1044 related articles for article (PubMed ID: 20039413)
1. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT; Neuwelt CM; Wallace DJ; Shanahan JC; Latinis KM; Oates JC; Utset TO; Gordon C; Isenberg DA; Hsieh HJ; Zhang D; Brunetta PG
Arthritis Rheum; 2010 Jan; 62(1):222-33. PubMed ID: 20039413
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
[TBL] [Abstract][Full Text] [Related]
3. Novel evidence-based systemic lupus erythematosus responder index.
Furie RA; Petri MA; Wallace DJ; Ginzler EM; Merrill JT; Stohl W; Chatham WW; Strand V; Weinstein A; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1143-51. PubMed ID: 19714615
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.
Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC
Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854
[TBL] [Abstract][Full Text] [Related]
5. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
Reddy V; Jayne D; Close D; Isenberg D
Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
Lai ZW; Kelly R; Winans T; Marchena I; Shadakshari A; Yu J; Dawood M; Garcia R; Tily H; Francis L; Faraone SV; Phillips PE; Perl A
Lancet; 2018 Mar; 391(10126):1186-1196. PubMed ID: 29551338
[TBL] [Abstract][Full Text] [Related]
7. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
Rodziewicz M; Dyball S; Lunt M; McDonald S; Sutton E; Parker B; Bruce IN;
Lancet Rheumatol; 2023 May; 5(5):e284-e292. PubMed ID: 38251591
[TBL] [Abstract][Full Text] [Related]
8. Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus.
Carter LM; Alase A; Wigston Z; Psarras A; Burska A; Sutton E; Yusof MYM; Reynolds JA; ; McHugh N; Emery P; Wittmann M; Bruce IN; Vital EM
Arthritis Rheumatol; 2023 May; 75(5):697-710. PubMed ID: 36409591
[TBL] [Abstract][Full Text] [Related]
9. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
[TBL] [Abstract][Full Text] [Related]
10. B-cell-depleting therapy in systemic lupus erythematosus.
Ramos-Casals M; Sanz I; Bosch X; Stone JH; Khamashta MA
Am J Med; 2012 Apr; 125(4):327-36. PubMed ID: 22444096
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus.
Lin TW; Lin YT; Hu YC; Yu HH; Chiang BL
Lupus Sci Med; 2024 Jan; 11(1):. PubMed ID: 38242722
[TBL] [Abstract][Full Text] [Related]
12. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
McDonnell SRP; Nguyen VA; Walton NM; Merkwirth C; Hong F; Berg D; Muensterman ET; Furie RA
Lupus Sci Med; 2024 Mar; 11(1):. PubMed ID: 38453421
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
Pirone C; Mendoza-Pinto C; van der Windt DA; Parker B; O Sullivan M; Bruce IN
Semin Arthritis Rheum; 2017 Dec; 47(3):384-396. PubMed ID: 28602359
[TBL] [Abstract][Full Text] [Related]
14. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Merrill JT; Guthridge J; Smith M; June J; Koumpouras F; Machua W; Askanase A; Khosroshahi A; Sheikh SZ; Rathi G; Burington B; Foster P; Matijevic M; Arora S; Wang X; Gao M; Wax S; James JA; Zack DJ
Arthritis Rheumatol; 2023 Dec; 75(12):2185-2194. PubMed ID: 37459248
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.
Vigna-Perez M; Hernández-Castro B; Paredes-Saharopulos O; Portales-Pérez D; Baranda L; Abud-Mendoza C; González-Amaro R
Arthritis Res Ther; 2006; 8(3):R83. PubMed ID: 16677395
[TBL] [Abstract][Full Text] [Related]
16. Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update.
Rodziewicz M; Mendoza-Pinto C; Dyball S; Munguía-Realpozo P; Parker B; Bruce IN
Semin Arthritis Rheum; 2024 Apr; 65():152346. PubMed ID: 38185077
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus.
Shah K; Cragg M; Leandro M; Reddy V
Biologicals; 2021 Jan; 69():1-14. PubMed ID: 33288390
[TBL] [Abstract][Full Text] [Related]
18. Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity.
Tian J; Kang S; Zhang D; Huang Y; Yao X; Zhao M; Lu Q
Lupus Sci Med; 2023 Oct; 10(2):. PubMed ID: 37798046
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models.
Reynolds JA; Prattley J; Geifman N; Lunt M; Gordon C; Bruce IN;
Arthritis Res Ther; 2021 Jul; 23(1):203. PubMed ID: 34321096
[TBL] [Abstract][Full Text] [Related]
20. Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response.
Balevic SJ; Niu J; Chen J; Green D; McMahon A; Hornik CP; Schanberg LE; Glaser R; Gonzalez D; Burckart GJ
J Clin Pharmacol; 2023 Jan; 63(1):105-118. PubMed ID: 35968821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
